|
Diabetes Technology & Therapeutics
Clinical Performance of a Continuous Viscometric Affinity Sensor for Glucose
To cite this article:
Peter Diem, Lucas Kalt, Ulrich Haueter, Lars Krinelke, Radko Fajfr, Bruno Reihl, Uwe Beyer.
Diabetes Technology & Therapeutics.
December 2004,
6(6): 790-799.
doi:10.1089/dia.2004.6.790.
Peter Diem, M.D.Division of Endocrinology and Diabetes, University of Bern–Inselspital, Bern, Switzerland. Lucas Kalt, M.D.Disetronic Medical Systems AG, Burgdorf, Switzerland. Ulrich Haueter Disetronic Medical Systems AG, Burgdorf, Switzerland. Lars Krinelke, M.D., Ph.D.Disetronic Medical Systems AG, Burgdorf, Switzerland. Radko Fajfr, M.D.Division of Endocrinology and Diabetes, University of Bern–Inselspital, Bern, Switzerland. Bruno Reihl, Ph.D.Disetronic Medical Systems AG, Burgdorf, Switzerland. Uwe Beyer, Ph.D.Disetronic Medical Systems AG, Burgdorf, Switzerland. Objective: A viscometric affinity sensor has been developed to measure the interstitial glucose concentration continuously. In a pilot clinical study its performance was assessed under conditions close to everyday life. Additionally, different insertion sites were tested for their suitability to apply subcutaneous glucose sensors. Methods: Twelve subjects, 10 of whom with type 1 diabetes, were examined for 8 h. Sensors were applied subcutaneously at the forearm and the abdomen of each subject. Capillary blood glucose references were obtained from the finger tip every 30 min. Retrospective calibration was carried out individually with Deming regression. Results: After retrospective calibration the 95% limits of agreement in the plot of the differences between sensor signals and references versus their means were ±60 mg/dL. The sensitivity of the sensors remained stable over the entire measuring period, without any significant differences between the sensors at forearm and abdomen. Correcting for the observed time delay of 15 min between references and sensor values the limits of agreements were reduced to ±38 mg/dL. Furthermore, error grid analysis showed 89.3% of the paired values in zone A and 9.6% in zone B. Only 1.1% were clinically unacceptable (zone D). Conclusions: The performance of the viscometric affinity sensor shows the potential of the measuring principle under in vivo conditions. Forearm and abdomen seem to be similarly well suited for the application of subcutaneous sensors. The signal stability over time and the absence of enzymatic, chemical, or electrode reactions are advantages of the viscometric affinity principle.  This paper was cited by:A MEMS viscometric sensor for continuous glucose monitoring Yongjun Zhao, Siqi Li, Arthur Davidson, Bozhi Yang, Qian Wang, Qiao Lin Journal of Micromechanics and Microengineering. Jan 2008, Vol. 17, No. 12: 2528-2537 CrossRef Recent progress in analytical instrumentation for glycemic control in diabetic and critically ill patients Venkata Radhakrishna Kondepati, H. Michael Heise Analytical and Bioanalytical Chemistry. Jun 2007, Vol. 388, No. 3: 545-563 CrossRef Continuous Glucose Monitoring Technology Delivers Detailed Diabetes Data David C. Klonoff Point of Care: The Journal of Near-Patient Testing & Technology. Oct 2006, Vol. 5, No. 3: 105-111 CrossRef In Vivo Performance Evaluation of a Transdermal Near- Infrared Fluorescence Resonance Energy Transfer Affinity Sensor for Continuous Glucose Monitoring Ralph Ballerstadt, Colton Evans, Ashok Gowda, Roger McNichols Diabetes Technology & Therapeutics. Jun 2006, Vol. 8, No. 3: 296-311 Abstract | Full Text PDF | Reprints & Permissions
|
|